Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to $587,000.

  • Lineage Cell Therapeutics' Depreciation & Amortization (CF) rose 26.24% to $178,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $664,000, marking a year-over-year increase of 14.68%. This contributed to the annual value of $587,000 for FY2024, which is 4.45% up from last year.
  • As of FY2024, Lineage Cell Therapeutics' Depreciation & Amortization (CF) stood at $587,000, which was up 4.45% from $562,000 recorded in FY2023.
  • Lineage Cell Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $823,000 for FY2020, and its period low was $562,000 during FY2023.
  • Its 3-year average for Depreciation & Amortization (CF) is $577,000, with a median of $582,000 in 2022.
  • In the last 5 years, Lineage Cell Therapeutics' Depreciation & Amortization (CF) declined by 19.44% in 2021 and then increased by 4.45% in 2024.
  • Yearly analysis of 5 years shows Lineage Cell Therapeutics' Depreciation & Amortization (CF) stood at $823,000 in 2020, then dropped by 19.44% to $663,000 in 2021, then declined by 12.22% to $582,000 in 2022, then fell by 3.44% to $562,000 in 2023, then increased by 4.45% to $587,000 in 2024.